Adrienne Graves Purchases 1,000 Shares of Harrow (NASDAQ:HROW) Stock

Harrow, Inc. (NASDAQ:HROW) Director Adrienne Graves acquired 1,000 shares of the business’s stock in a transaction on Monday, May 18th. The shares were bought at an average cost of $31.07 per share, with a total value of $31,070.00. Following the completion of the acquisition, the director owned 1,000 shares in the company, valued at approximately $31,070. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Harrow Trading Up 0.6%

Shares of HROW opened at $30.86 on Thursday. The company has a 50 day simple moving average of $36.21 and a two-hundred day simple moving average of $42.02. Harrow, Inc. has a 1 year low of $25.21 and a 1 year high of $54.85. The company has a debt-to-equity ratio of 10.30, a current ratio of 2.48 and a quick ratio of 2.30. The firm has a market cap of $1.15 billion, a P/E ratio of -75.27 and a beta of 0.34.

Harrow (NASDAQ:HROW) last posted its earnings results on Monday, May 11th. The company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.31). Harrow had a negative net margin of 5.57% and a positive return on equity of 19.59%. The business had revenue of $44.20 million during the quarter, compared to analysts’ expectations of $52.43 million. During the same period last year, the business posted ($0.38) earnings per share. On average, equities analysts expect that Harrow, Inc. will post 0.29 earnings per share for the current fiscal year.

Institutional Trading of Harrow

Several institutional investors and hedge funds have recently made changes to their positions in HROW. University of Texas Texas AM Investment Management Co. bought a new stake in shares of Harrow during the fourth quarter worth $26,000. KBC Group NV bought a new stake in shares of Harrow during the first quarter worth $31,000. Raymond James Financial Inc. bought a new stake in shares of Harrow during the second quarter worth $48,000. SBI Securities Co. Ltd. lifted its position in shares of Harrow by 393.5% during the fourth quarter. SBI Securities Co. Ltd. now owns 1,061 shares of the company’s stock worth $52,000 after purchasing an additional 846 shares during the last quarter. Finally, State of Alaska Department of Revenue bought a new stake in shares of Harrow during the third quarter worth $83,000. 72.76% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research firms recently weighed in on HROW. Nomura lowered shares of Harrow to a “neutral” rating in a report on Wednesday, March 18th. Zacks Research raised shares of Harrow from a “strong sell” rating to a “hold” rating in a report on Friday, April 3rd. BTIG Research reissued a “buy” rating and issued a $63.00 target price on shares of Harrow in a report on Tuesday, May 12th. HC Wainwright restated a “buy” rating and issued a $70.00 price target on shares of Harrow in a research report on Thursday, March 19th. Finally, B. Riley Financial restated a “buy” rating and issued a $65.00 price target (down from $74.00) on shares of Harrow in a research report on Tuesday, April 7th. Eight investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $69.43.

Key Headlines Impacting Harrow

Here are the key news stories impacting Harrow this week:

• Positive Sentiment: Director Adrienne L. Graves bought 1,000 shares at $31.07, a modest insider purchase that can be interpreted as confidence in Harrow’s outlook. SEC filing
• Positive Sentiment: HC Wainwright kept a Buy rating and $70 price target, signaling meaningful upside potential from current trading levels.
• Positive Sentiment: HC Wainwright raised its Q4 2026 EPS estimate to $0.61 from $0.40, suggesting expectations for stronger profitability later in the cycle.
• Neutral Sentiment: Other recent commentary, including a Seeking Alpha piece, framed Harrow as having attractive demand but a valuation that still looks like a hold.
• Neutral Sentiment: B. Riley trimmed its price target to $60 from $65 while keeping a Buy rating, reflecting continued optimism but slightly less enthusiasm.
• Negative Sentiment: HC Wainwright cut its FY2026 EPS estimate to $0.15 from $0.56 and reduced its Q2 2026 EPS outlook to $0.01, pointing to near-term earnings pressure.
• Negative Sentiment: Harrow’s last quarterly report missed estimates on both earnings and revenue, reinforcing concerns that execution has been uneven even as analysts remain bullish longer term.

Harrow Company Profile

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.